Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 28;11(8):295.
doi: 10.21037/atm-23-352. Epub 2023 Feb 23.

Challenges for clinical application of "TRACEBACK" study: testing of historical Tubo-Ovarian cancer patients for hereditary risk genes

Masayuki Sekine  1 , Masanori Isobe  1 , Koji Nishino  1 , Sosuke Adachi  1 , Kazuaki Suda  1 , Kosuke Yoshihara  1
Affiliations
Editorial

Challenges for clinical application of "TRACEBACK" study: testing of historical Tubo-Ovarian cancer patients for hereditary risk genes

Masayuki Sekine et al. Ann Transl Med. .
No abstract available

Keywords: BRCA; Ovarian cancer; TRACEBACK; genetic testing.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-352/coif). MS received lecture fees from AstraZeneca. KY received lecture fees and a research grant from AstraZeneca. The other authors have no conflicts of interest to declare.

Comment on

  • TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study. Delahunty R, et al. J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9. J Clin Oncol. 2022. PMID: 35263119 Free PMC article.

References

    1. Delahunty R, Nguyen L, Craig S, et al. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. J Clin Oncol 2022;40:2036-47. 10.1200/JCO.21.02108 - DOI - PMC - PubMed
    1. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010;28:893-901. 10.1200/JCO.2009.27.0660 - DOI - PubMed
    1. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012;118:510-7. 10.1002/cncr.26294 - DOI - PMC - PubMed
    1. Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer 2011;117:5334-43. 10.1002/cncr.26166 - DOI - PubMed
    1. Sekine M, Nishino K, Enomoto T. Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location. Genes (Basel) 2021;12:1050. 10.3390/genes12071050 - DOI - PMC - PubMed